The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of ...

Chinese drug maker 3SBio has licensed its new cancer drug to US pharmaceutical giant Pfizer in the largest deal ever for China’s biotech industry, underscoring the strong commercial Sino-US ties ...

The acquisition of SSGJ-707 coincides with Pfizer and Summit collaborating on clinical trials that combine Pfizer’s antibody-drug conjugates (ADCs) with Summit’s Ivosidenib (Ivo).

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer has entered into an exclusive global, ex-China, licensing agreement with 3SBio a Chinese biopharmaceutical company, listed on the Hong Kong Stock Exchange (HKEX), according to a May 19 company ...

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...